Plain-English translation of NCT06787105 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study—meaning researchers are watching and collecting information rather than randomly assigning people to different treatments. The study is following patients with metastatic colorectal cancer (cancer that has spread to other parts of the body) who are receiving fruquintinib as their next treatment option. Researchers want to understand how well this medication works in real-world medical practice, and they're also collecting tumor tissue and blood samples to learn which patients benefit most from the treatment.
Patients with advanced colorectal cancer who have already tried several standard treatments often have limited options left. This medication represents a newer choice, but doctors need better real-world information about how effective it truly is and which patients are most likely to respond well to it.
You likely qualify if…
You likely don't qualify if…
You will receive fruquintinib as prescribed by your regular oncology team as part of your standard care—this is not an experimental arm where you're being assigned a new treatment. Researchers will collect information from your medical records about how you're responding to the medication over time. You'll also be asked to donate a sample of tumor tissue (archival tissue from previous biopsies) and provide blood samples during your routine blood draws so scientists can study what makes certain patients respond better to this treatment. The study involves about 150 patients across 50 clinical sites in Germany.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
Germany